High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.

Nie Y, Staley A, Hinz TK, Perez-Johnston R, Merrick DT, Yang MC, Davies KD, Bunn PA, Aisner DL, Camidge DR, Schenk EL, Heasley LE, Patil T

Open source

DOI
10.1016/j.cllc.2026.04.010
Published
2026 Jun
Container
Clinical lung cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2026.04.010,
  title = {High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.},
  author = {Nie Y and Staley A and Hinz TK and Perez-Johnston R and Merrick DT and Yang MC and Davies KD and Bunn PA and Aisner DL and Camidge DR and Schenk EL and Heasley LE and Patil T},
  year = {2026},
  journal = {Clinical lung cancer},
  doi = {10.1016/j.cllc.2026.04.010},
  url = {https://doi.org/10.1016/j.cllc.2026.04.010}
}

RIS

TY  - JOUR
TI  - High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.
AU  - Nie Y
AU  - Staley A
AU  - Hinz TK
AU  - Perez-Johnston R
AU  - Merrick DT
AU  - Yang MC
AU  - Davies KD
AU  - Bunn PA
AU  - Aisner DL
AU  - Camidge DR
AU  - Schenk EL
AU  - Heasley LE
AU  - Patil T
PY  - 2026
JO  - Clinical lung cancer
DO  - 10.1016/j.cllc.2026.04.010
UR  - https://doi.org/10.1016/j.cllc.2026.04.010
ER  - 

APA

Y, N., A, S., TK, H., R, P., DT, M., MC, Y., KD, D., PA, B., DL, A., DR, C., EL, S., LE, H., & T, P. (2026). High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.. Clinical lung cancer. https://doi.org/10.1016/j.cllc.2026.04.010

Source records